10x Genomics has launched its Chromium Single Cell Immune Profiling v2 product. The new product extends the capabilities of the original version, supporting breakthroughs in immunology, oncology, autoimmunity, inflammation, transplant biology, and infectious diseases. It also builds on the existing product that is being used by researchers to understand COVID-19 to advance science for the development of vaccines, antiviral drugs and clinical treatments related to the SARS-CoV-2 viral infection.
The new Chromium Single Cell Immune Profiling v2 product provides a comprehensive approach to simultaneously examine cellular heterogeneity of the immune system, T and B cell repertoire diversity, and antigen specificity at single cell resolution. Researchers can profile thousands of genes and hundreds of cell surface proteins, cell by cell and at scale, with enhanced sensitivity, resolution, and sequencing quality. The latest product offers up to a 60 percent increase in gene detection sensitivity, allowing users greater flexibility in reducing sequencing costs without a loss in gene diversity or accessing rare gene transcripts without an increase in cost.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Using the Chromium Single Cell Immune Profiling v2 product, researchers can:
- Characterize adaptive and innate immune cell diversity
- Identify and characterize rare cell types and biomarkers
- Analyze tissue microenvironment, disease progression, and drug immune response
- Perform large-scale antibody and TCR discovery for novel antigens
- Characterize immune responses to infection by measuring clonal expansions and immune cell phenotypes
- Focus on relevant genes and pathways with predesigned gene expression panels for immunology, oncology, and drug discovery, or design a fully custom panel
“With the number of coronavirus cases expected to reach 100,000 a day in the US alone, it is critical that we get the right products into the hands of scientists as soon as possible,” said Ben Hindson, co-founder and chief scientific officer of 10x Genomics. “Our new product adds a powerful tool to our customers’ arsenal for combating COVID-19 and other deadly diseases, and is a testimony to our very rich product pipeline.”